Table 4 Sensitivity analyses: key scenarios and corresponding ICERs and absolute cost differences for SPG versus medical management cohorts
Scenario | ICER | Absolute cost difference, SPG vs. control (€) |
|---|---|---|
(€/QALY) | ||
Base case | 2,736 | +889 |
Base case (undiscounted) | SPG dominating | −1,477 |
Pain relief 50.2 % (lower bound of 95 % CI) | 18,846 | 6,125 |
Pain relief 80.5 % (upper bound of 95 % CI) | SPG dominating | −3,262 |
1.37 CH attacks per day (50 % of baseline) | 50,590 | 16,442 |
4.11 CH attacks per day (150 % of baseline) | SPG dominating | −14,664 |
Utilization (cost) of attack-ending meds +25 % | SPG dominating | −6,887 |
Utilization (cost) of attack-ending meds −25 % | €26,663 | 8,665 |
No frequency response considered for SPG | 13,180 | 4,284 |
Average frequency reduction low (15 %) | 8,126 | 2,641 |
Average frequency reduction high (50 %) | SPG dominating | −1,191 |
No annual change in frequency response | 220 | 72 |
Absolute annual reduction in frequency response of 6.2 % (double of base case assumption of 3.1 %) | 5,251 | 1,707 |
Sumatriptan s.c. used by every patient (at dosage reported by [7], frequency-adjusted to Pathway CH-1; total medication cost per attack: €18.81) | SPG dominating | −33,609 |
Every attack treated by maximum guideline-defined medication dosages (total medication cost per attack: €56.66) | SPG dominating | −165,618 |
Assumption that stimulation device in required revisions would be paid by payers, as opposed to the manufacturer | 12,351 | 4,014 |
Reduced timeframe of analysis 3.5 years | 40,058 | 9,537 |
Extended timeframe of analysis 7.0 years | SPG dominating | −9,857 |